An interventional study of Resuscitation (Ventor) in Cardiac Arrest (CA), sponsored by CoLabs Medical. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by CoLabs Medical · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Heart Arrest with a site in United States — 40 open to participants now, 45 under way, 2 of them phase 3. Heart Arrest · United States.
Among the 171 studies in Heart Arrest with a site in United States, this one is the 85th largest by planned enrollment of the 117 interventional ones that give a count, is one of 13 that started in 2025, is one of 67 with no phase, reaches primary completion later than 14 of the 44 other live ones, and was the 151st registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →40 of the 171 studies in Heart Arrest with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
University of Massachusetts, Worcester · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 1 days–17 yrs
Mayo Clinic · Sites in United States
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 0 days–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 24 · Phase 3 12 · Phase 4 4
First in 2002; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 72 across the 117 interventional studies, 157 across the 54 observational. Of the 114 that completed or were terminated, 50 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 171 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with CoLabs Medical as lead sponsor.
CoLabs Medical has 1 study filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
17 of the studies in Heart Arrest with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05283850Phase 3Carol BernierSurviving PEA in Roanoke (SPEAR) Study | 2027-02 |
| NCT06109181Lexeo TherapeuticsGene Therapy for ACM Due to a PKP2 Pathogenic Variant | 2026-12 |
| NCT05893420AgileMD, Inc.A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning | 2026-12-31 |
| NCT02664831MaineHealthImmunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS) | 2027-01 |
| NCT07656259Mayo ClinicCOMPARE-VENT Feasibility Pilot Study | 2027-02-28 |
Add all 17 to your calendar (.ics) → With an account.
Among the 171 studies in Heart Arrest with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the initial safety and effectiveness of the Ventor Airway System in providing short-term ventilation support in non-breathing subjects during cardiopulmonary resuscitation (CPR) and respiratory arrests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Known esophageal disease or facial/perforating neck trauma defined as study candidates with the following medical history:
Subjects being treated with Ventor device
Device: Resuscitation (Ventor)
Resuscitation with the Ventor device
Ability to provide oxygenation during CPR
As measured through the monitoring of intra-arrest PaO2
Time frame: From device insertion through 1 hour.
Ability to provide ventilation during CPR
As measured through the monitoring of intra-arrest PaCO2
Time frame: From device insertion through 1 hour
Ability to provide oxygenation during CPR
As measured through the monitoring of intra-arrest cerebral oximetry
Time frame: From device insertion through 1 hour
Number of participants with device-related adverse events
Number and rate of adverse events
Time frame: From device insertion through 3 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Jun 2027, 26 months after the start.
Of 219 interventional studies with no phase under Heart Arrest, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 26 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.